{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:09:49Z","timestamp":1787314189363,"version":"build-2736575974"},"reference-count":32,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pharmacokinetics, efficacy, and safety of the Androderm testosterone (T) transdermal system (TTD) and intramuscular T enanthate injections (IM) for the treatment of male hypogonadism were compared in a 24-week multicenter, randomized, parallel-group study. Sixty-six adult hypogonadal men (22\u201365 years of age) were withdrawn from prior IM treatment for 4\u20136 weeks and then randomly assigned to treatment with TTD (two 2.5-mg systems applied nightly) or IM (200 mg injected every 2 weeks); there were 33 patients per group. Twenty-six patients in the TTD group and 32 in the IM group completed the study.<\/jats:p>\n                  <jats:p>TTD treatment produced circadian variations in the levels of total T, bioavailable T, dihydrotestosterone, and estradiol within the normal physiological ranges. IM treatment produced supraphysiological levels of T, bioavailable T, and estradiol (but not dihydrotestosterone) for several days after each injection. Mean morning sex hormone levels were within the normal range in greater proportions of TTD patients (range, 77\u2013100%) than IM patients (range, 19\u201384%). Both treatments normalized LH levels in approximately 50% of patients with primary hypogonadism; however, LH levels were suppressed to the subnormal range in 31% of IM patients vs. 0% of TTD patients. Both treatments maintained sexual function (assessed by questionnaire and Rigiscan) and mood (Beck Depression Inventory) at the prior treatment levels.<\/jats:p>\n                  <jats:p>Prostate-specific antigen levels, prostate volumes, and lipid and serum chemistry parameters were comparable in both treatment groups. Transient skin irritation from the patches was reported by 60% of the TTD patients, but caused only three patients (9%) to discontinue treatment. IM treatment produced local reactions in 33% of patients and was associated with significantly more abnormal hematocrit elevations (43.8% of patients) compared with TTD treatment (15.4% of patients). Gynecomastia resolved more frequently during TTD treatment (4 of 10 patients) than with IM treatment (1 of 9 patients).<\/jats:p>\n                  <jats:p>Although both treatments seem to be efficacious for replacing T in hypogonadal men, the more physiological sex hormone levels and profiles associated with TTD may offer possible advantages over IM in minimizing excessive stimulation of erythropoiesis, preventing\/ameliorating gynecomastia, and not over-suppressing gonadotropins.<\/jats:p>","DOI":"10.1210\/jcem.84.10.6078","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T12:03:58Z","timestamp":1389182638000},"page":"3469-3478","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men*"],"prefix":"10.1210","volume":"84","author":[{"given":"Adrian S.","family":"Dobs","sequence":"first","affiliation":[{"name":"Johns Hopkins Medical Center (A.S.D.), Baltimore, Maryland 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Wayne","family":"Meikle","sequence":"additional","affiliation":[{"name":"Departments of Medicine (A.W.M.), Salt Lake City, Utah 84132"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Arver","sequence":"additional","affiliation":[{"name":"Karolinska Hospital (S.A.), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Sanders","sequence":"additional","affiliation":[{"name":"TheraTech Inc. (S.W.S., K.E.C., N.A.M.), Salt Lake City, Utah 84108"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.","family":"Caramelli","sequence":"additional","affiliation":[{"name":"TheraTech Inc. (S.W.S., K.E.C., N.A.M.), Salt Lake City, Utah 84108"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman A.","family":"Mazer","sequence":"additional","affiliation":[{"name":"Pharmaceutics (N.A.M.), University of Utah, Salt Lake City, Utah 84132"},{"name":"TheraTech Inc. (S.W.S., K.E.C., N.A.M.), Salt Lake City, Utah 84108"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613404422800_R1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0889-8529(18)30072-0","article-title":"Hormonal therapy of male hypogonadism.","volume":"23","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071613404422800_R2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jcem-51-6-1335","article-title":"Treatment of male hypogonadism with testosterone enanthate.","volume":"51","author":"Snyder","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R3","author":"Mazer","year":"1993"},{"key":"2020071613404422800_R4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1210\/jcem-68-2-369","article-title":"Treatment of primary hypogonadism in men by the transdermal administration of testosterone.","volume":"68","author":"Findlay","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R5"},{"key":"2020071613404422800_R6","year":"1999"},{"key":"2020071613404422800_R7","year":"1999"},{"key":"2020071613404422800_R8","first-page":"623","article-title":"Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.","volume":"74","author":"Meikle","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R9","first-page":"1832","volume":"815","author":"Meikle","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R10","author":"Meikle","year":"1995"},{"key":"2020071613404422800_R11","author":"Meikle","year":"1998"},{"key":"2020071613404422800_R12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0022-5347(01)66141-X","article-title":"Improvement in sexual function in testosterone-deficient men treated for one year with a permeation enhanced testosterone transdermal system.","volume":"155","author":"Arver","year":"1996","journal-title":"J Urol"},{"key":"2020071613404422800_R13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1210\/jcem-48-6-955","article-title":"Effects of androgen on sexual behavior in hypogonadal men.","volume":"48","author":"Davidson","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00006199-198231050-00006","article-title":"Sexual functioning, health beliefs, and compliance with high blood pressure medications.","volume":"31","year":"1982","journal-title":"Nursing Res"},{"key":"2020071613404422800_R15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"2020071613404422800_R16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1365-2265.1997.3071113.x","article-title":"Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.","volume":"47","author":"Arver","year":"1997","journal-title":"Clin Endocrinol"},{"key":"2020071613404422800_R17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0015-0282(16)46108-X","article-title":"Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men.","volume":"37","author":"Sokol","year":"1982","journal-title":"Fertil Steril"},{"key":"2020071613404422800_R18","author":"Behre","year":"1998"},{"key":"2020071613404422800_R19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1210\/jcem-73-3-609","article-title":"Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men.","volume":"73","author":"Finkelstein","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jcem-73-3-621","article-title":"Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men.","volume":"73","author":"Finkelstein","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1056\/NEJM199302183280708","article-title":"Current concepts: gynecomastia.","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"2020071613404422800_R22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJM197307122890205","article-title":"Androgens and erythropoiesis.","volume":"289","year":"1973","journal-title":"N Engl J Med"},{"key":"2020071613404422800_R23","first-page":"191","article-title":"The role of androgens in the treatment of hematologic disorders.","volume":"34","year":"1982","journal-title":"Adv Intern Med"},{"key":"2020071613404422800_R24","author":"Gooren","year":"1990"},{"key":"2020071613404422800_R25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0022-5347(17)38168-5","article-title":"Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence.","volume":"146","author":"Krauss","year":"1991","journal-title":"J Urol"},{"key":"2020071613404422800_R26","first-page":"1092","article-title":"Effects of testosterone supplementation in the aging male.","volume":"75","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R27"},{"key":"2020071613404422800_R28"},{"key":"2020071613404422800_R29","first-page":"75","article-title":"Clinical review 85: emerging issues in androgen replacement therapy.","volume":"74","author":"Bhasin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613404422800_R30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0190-9622(90)70113-V","article-title":"Adverse dermatologic reactions to transdermal drug delivery systems.","volume":"22","author":"Hogan","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2020071613404422800_R31","first-page":"299","volume":"20","author":"Wilson","year":"1998"},{"key":"2020071613404422800_R32"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/10\/3469\/9058666\/jcem3469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/84\/10\/3469\/9058666\/jcem3469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T20:23:06Z","timestamp":1594930986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/84\/10\/3469\/2660490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.84.10.6078","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10,1]]}}}